Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Nasdaq Clean Edge Global Water UCITS ETF 05.06.2026 H2O LN IE000Q8F0M81 600,002.00 USD 11,831,342.51 19.719  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - October 05.06.2026 FOCT.LN IE0004X8KUG5 100,002.00 USD 2,881,032.36 28.810  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest U.S. Equity Buffer UCITS ETF - July 05.06.2026 FJUL.LN IE000YJBT6I5 100,002.00 USD 2,820,570.61 28.205  ...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Vest US Equity Max Buffer UCITS ETF - December 05.06.2026 MDEC.LN IE0007FIJUO5 50,002.00 USD 1,401,021.87 28.019  ...
-

Altius Minerals Corporation to Join the S&P/TSX Composite Index

ST. JOHN’S, Newfoundland and Labrador--(BUSINESS WIRE)--Altius Minerals Corporation (TSX: ALS; OTCQX: ATUSF) (“Altius” or the “Corporation”) announces that its common shares will be added to the S&P/TSX Composite Index, effective prior to the open of trading on Monday, June 22, 2026, as disclosed by S&P Dow Jones Indices on June 5, 2026. The S&P/TSX Composite Index is Canada’s premier equity benchmark, comprising the largest and most actively traded companies listed on the Toronto S...
-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 05.06.2026 FTEG.LN IE0009F7UB30 125,002.00 EUR 2,640,150.68 21.121  ...
-

APi Group Debuts on the Fortune 500 List

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--APi Group Corporation (NYSE: APG) (“APi” or the “Company”), a global, market-leading business services provider of safety and specialty services, today announced its debut on the 2026 Fortune 500 list, earning the No. 486 position. The annual ranking, published by Fortune magazine, recognizes the 500 largest U.S. corporations by total revenue for the prior fiscal year. APi Group earned its place on the list with $7.9 billion in 2025 revenue, reflecting a lo...
-

Valvoline Instant Oil Change® Introduces The Ride Wrangler℠ to Remind Drivers to Change Wisely℠

LEXINGTON, Ky.--(BUSINESS WIRE)--Valvoline Instant Oil Change is setting out to redefine the quick oil change category with the launch of “The Ride Wrangler,” a new integrated brand campaign developed in partnership with creative agency 3Headed Monster. At a time when many quick service brands compete on speed, discounts, and pressure tactics, Valvoline Instant Oil Change is positioning itself as the smart choice for drivers looking for trusted expertise and confidence in their vehicle care dec...
-

Estancia Capital Management, LLC Announces Final Close of Estancia Capital Partners Fund III, LP, its Largest Fund to Date

SCOTTSDALE, Ariz. & PHILADELPHIA--(BUSINESS WIRE)--Estancia Capital Management (“Estancia”), a specialist private equity firm investing in lower middle-market financial services companies, today announced the successful final closing for its third buyout fund, Estancia Capital Partners Fund III, L.P. and its affiliated investment vehicles (“ECP III”). ECP III secured $367 million in commitments with a target of $350 million. With this closing, Estancia’s regulatory assets under management are a...
-

Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome

NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the successful completion of dosing in the Embolden™ registrational trial of NGN-401, an investigational gene therapy designed to be a potential best-in-class, one-time treatment for Rett syndrome. While the initial enrollment target was 20 participants, the statistical analysis plan p...